Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Symptomatic Bullous Pemphigoid (FJORD)
jRCT2071210014Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Complete remission off oral corticosteroids at Week 36. Started Mar 2021; status: completed.
02
Drugs
benralizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on jRCT2071210014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210014.